354 related articles for article (PubMed ID: 29718973)
1. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Piera-Velazquez S; Jimenez SA
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
[TBL] [Abstract][Full Text] [Related]
3. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
4. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
[TBL] [Abstract][Full Text] [Related]
6. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
7. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
[TBL] [Abstract][Full Text] [Related]
8. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.
Liang R; Šumová B; Cordazzo C; Mallano T; Zhang Y; Wohlfahrt T; Dees C; Ramming A; Krasowska D; Michalska-Jakubus M; Distler O; Schett G; Šenolt L; Distler JH
Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816
[TBL] [Abstract][Full Text] [Related]
9. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo.
Ishida W; Mori Y; Lakos G; Sun L; Shan F; Bowes S; Josiah S; Lee WC; Singh J; Ling LE; Varga J
J Invest Dermatol; 2006 Aug; 126(8):1733-44. PubMed ID: 16741519
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4.
Wermuth PJ; Mendoza FA; Jimenez SA
Lab Invest; 2019 Apr; 99(4):470-482. PubMed ID: 30470772
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
12. Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis.
Tomcik M; Palumbo-Zerr K; Zerr P; Sumova B; Avouac J; Dees C; Distler A; Becvar R; Distler O; Schett G; Senolt L; Distler JH
Ann Rheum Dis; 2016 Mar; 75(3):609-16. PubMed ID: 25603829
[TBL] [Abstract][Full Text] [Related]
13. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
[TBL] [Abstract][Full Text] [Related]
15. In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.
Fineschi S; Bongiovanni M; Donati Y; Djaafar S; Naso F; Goffin L; Argiroffo CB; Pache JC; Dayer JM; Ferrari-Lacraz S; Chizzolini C
Am J Respir Cell Mol Biol; 2008 Oct; 39(4):458-65. PubMed ID: 18458239
[TBL] [Abstract][Full Text] [Related]
16. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
[TBL] [Abstract][Full Text] [Related]
17. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
18. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
[TBL] [Abstract][Full Text] [Related]
19. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
[TBL] [Abstract][Full Text] [Related]
20. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA
Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
